{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59","value":"70.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"395"}],"units":"Participants"}],"title":"Cycle 1 Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"82","value":"64.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"401"}],"units":"Participants"}],"title":"Cycle 2 Day 14"}],"denoms":[{"counts":[{"groupId":"OG000","value":"423"}],"units":"Participants"}],"description":"Summary of plasma palbociclib within-participant mean steady-state trough concentrations.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received letrozole 2.5 milligram (mg) orally QD (once daily) combined with palbociclib 125 mg QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG000","title":"Palbociclib Plus Letrozole"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was a subset of AT participants, who were treated with Palbociclib and had at least one measured plasma concentration. Here \"Number Analyzed\" signifies number of participants evaluable for specified rows.","reportingStatus":"POSTED","timeFrame":"0 hour (predose) on Day 14 of cycles 1 and 2","title":"Observed Plasma Trough Concentration (Ctrough) at Steady-State","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter (ng/mL)"}